Clal Biotechnology Industries Ltd (CBI) - Total Assets
Based on the latest financial reports, Clal Biotechnology Industries Ltd (CBI) holds total assets worth ILA52.12 Million ILA (≈ $139.73K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Clal Biotechnology Industries Ltd (CBI) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Clal Biotechnology Industries Ltd - Total Assets Trend (2006–2024)
This chart illustrates how Clal Biotechnology Industries Ltd's total assets have evolved over time, based on quarterly financial data. See net assets of Clal Biotechnology Industries Ltd for net asset value and shareholders' equity analysis.
Clal Biotechnology Industries Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Clal Biotechnology Industries Ltd's total assets of ILA52.12 Million consist of 8.6% current assets and 91.4% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 5.8% |
| Accounts Receivable | ILA505.00K | 0.8% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2006–2024)
This chart illustrates how Clal Biotechnology Industries Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CBI market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Clal Biotechnology Industries Ltd's current assets represent 8.6% of total assets in 2024, a decrease from 33.7% in 2006.
- Cash Position: Cash and equivalents constituted 5.8% of total assets in 2024, down from 32.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
Clal Biotechnology Industries Ltd Competitors by Total Assets
Key competitors of Clal Biotechnology Industries Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Genfit S.A.
PA:GNFT
|
France | €157.93 Million |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
Altimmune Inc
NASDAQ:ALT
|
USA | $279.93 Million |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$255.67 Million |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
China | CN¥1.48 Billion |
Clal Biotechnology Industries Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.11 | 2.18 | 2.73 |
| Quick Ratio | 0.11 | 2.18 | 2.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA-15.98 Million | ILA5.56 Million | ILA77.58 Million |
Clal Biotechnology Industries Ltd - Advanced Valuation Insights
This section examines the relationship between Clal Biotechnology Industries Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.12 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -57.3% |
| Total Assets | ILA67.69 Million |
| Market Capitalization | $11.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values Clal Biotechnology Industries Ltd's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Clal Biotechnology Industries Ltd's assets decreased by 57.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Clal Biotechnology Industries Ltd (2006–2024)
The table below shows the annual total assets of Clal Biotechnology Industries Ltd from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA67.69 Million ≈ $181.47K |
-57.26% |
| 2023-12-31 | ILA158.39 Million ≈ $424.63K |
-13.30% |
| 2022-12-31 | ILA182.69 Million ≈ $489.79K |
-58.94% |
| 2021-12-31 | ILA444.92 Million ≈ $1.19 Million |
-27.54% |
| 2020-12-31 | ILA614.03 Million ≈ $1.65 Million |
-0.48% |
| 2019-12-31 | ILA616.97 Million ≈ $1.65 Million |
-39.28% |
| 2018-12-31 | ILA1.02 Billion ≈ $2.72 Million |
-1.77% |
| 2017-12-31 | ILA1.03 Billion ≈ $2.77 Million |
-7.54% |
| 2016-12-31 | ILA1.12 Billion ≈ $3.00 Million |
-27.01% |
| 2015-12-31 | ILA1.53 Billion ≈ $4.11 Million |
-9.17% |
| 2014-12-31 | ILA1.69 Billion ≈ $4.52 Million |
-12.17% |
| 2013-12-31 | ILA1.92 Billion ≈ $5.15 Million |
+9.83% |
| 2012-12-31 | ILA1.75 Billion ≈ $4.69 Million |
+39.89% |
| 2011-12-31 | ILA1.25 Billion ≈ $3.35 Million |
-8.32% |
| 2010-12-31 | ILA1.36 Billion ≈ $3.66 Million |
+45.67% |
| 2009-12-31 | ILA936.32 Million ≈ $2.51 Million |
+119.83% |
| 2008-12-31 | ILA425.92 Million ≈ $1.14 Million |
+1.30% |
| 2007-12-31 | ILA420.47 Million ≈ $1.13 Million |
+226.50% |
| 2006-12-31 | ILA128.78 Million ≈ $345.26K |
-- |
About Clal Biotechnology Industries Ltd
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to i… Read more